Table 3.
Univariable analysis of potential preditive factors of overall survival
Univariable analysis | Multivariable analysis | ||||||
---|---|---|---|---|---|---|---|
Variable | HR | 95 % CI | p | Median OS [m] | HR | 95 % CI | p |
Age (< vs. > = median of 61 years) | 1.18 | 0.8–1.7 | 0.4 | 14 vs. 12 | – | – | – |
Gender (m vs. f) | 0.62 | 0.4–0.95 | 0.028 (*) | 11 vs. 16 | 0.64 | 0.38–1.08 | 0.095 |
KPS (< vs. > = median of 70 %) | 0.96 | 0.94–0.98 | <0.001 (*) | 9 vs. 15 | – | – | – |
MGMT-status (methylated vs. unmethylated) | 1.68 | 1.08–2.61 | 0.021 (*) | 16 vs. 11 | 1.89 | 1.158–3.09 | 0.011 (*) |
Localization (other vs. central) | 1.71 | 0.83–3.56 | 0.15 | 13 vs. 13 | – | – | – |
PTV (< vs. > = median of 337 ccm) | 1.37 | 0.93–2.02 | 0.11 | 14 vs. 12 | 1.61 | 1–2.6 | 0.048 (*) |
Subtotal resection or biopsy vs. gross total resection | 0.64 | 0.43–0.95 | 0.025 (*) | 11 vs. 15 | 0.62 | 0.39–0.98 | 0.041 (*) |
Fractionation regimen (NFRT vs. AHFRT) | 1.16 | 0.79–1.71 | 0.46 | 15 vs. 10 | – | – | – |
(*) p-value ≤ 0.05, HR hazard ratio, CI confidence interval, OS overall survival, KPS Karnofsky performance status, MGMT O-6-methylguanine-DNA methyltransferase, PTV planning target volume, NFRT normofractionated radiotherapy, AHFRT accelerated hyperfractionated radiotherapy